$17.08
1.04% yesterday
Nasdaq, Feb 28, 05:15 pm CET
ISIN
ANN6748L1027
Symbol
OFIX

Orthofix International NV Stock price

$17.26
-1.11 6.04% 1M
-0.06 0.35% 6M
-0.20 1.15% YTD
+3.80 28.23% 1Y
-16.72 49.21% 3Y
-19.23 52.70% 5Y
-14.94 46.40% 10Y
Nasdaq, Closing price Wed, Feb 26 2025
-0.25 1.43%
ISIN
ANN6748L1027
Symbol
OFIX
Sector

Key metrics

Market capitalization $671.58m
Enterprise Value $779.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.98
P/S ratio (TTM) P/S ratio 0.84
P/B ratio (TTM) P/B ratio 1.32
Revenue growth (TTM) Revenue growth 7.08%
Revenue (TTM) Revenue $799.49m
EBIT (operating result TTM) EBIT $-77.52m
Free Cash Flow (TTM) Free Cash Flow $-8.96m
Cash position $85.74m
EPS (TTM) EPS $-3.30
P/E forward negative
P/S forward 0.82
EV/Sales forward 0.95
Short interest 1.80%
Show more

Is Orthofix International NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Orthofix International NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Orthofix International NV forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Orthofix International NV forecast:

Buy
80%
Hold
20%

Financial data from Orthofix International NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
799 799
7% 7%
100%
- Direct Costs 271 271
2% 2%
34%
528 528
13% 13%
66%
- Selling and Administrative Expenses 472 472
1% 1%
59%
- Research and Development Expense 74 74
8% 8%
9%
-17 -17
80% 80%
-2%
- Depreciation and Amortization 60 60
13% 13%
8%
EBIT (Operating Income) EBIT -78 -78
45% 45%
-10%
Net Profit -126 -126
17% 17%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Orthofix International NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orthofix International NV Stock News

Neutral
Business Wire
3 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compa...
Neutral
Business Wire
11 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 9:00 am PT. Interested parties can access the live and archived webcast of the presentation in...
Neutral
Business Wire
about one month ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may acces...
More Orthofix International NV News

Company Profile

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Head office Curaçao
CEO Massimo Calafiore
Employees 1,616
Founded 1987
Website www.orthofix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today